Analysis & ranking
PHASE 2 — Evidence and Impact Analysis
Article 1 — RECO-Cas liquid biopsy SNV profiling (PMID 42172311)
🔴 Early cancer detection | Science Advances | Technical validation with clinical samples
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 8 | CRISPR-Cas12a + Argonaute nicking hybrid achieving 0.01% VAF is a meaningful step beyond current ddPCR/NGS sensitivity floors; POC integration on smartphone is genuinely novel combination |
| Clinical Relevance | 7 | Direct application to KRAS/EGFR/PIK3CA mutation monitoring; POC format addresses a real access barrier — but clinical utility unproven beyond analytical validation |
| Population Reach | 8 | These mutations span lung, colorectal, pancreatic, and breast cancers — extremely broad potential reach |
| Implementation Speed | 3 | Abstract-only; technical validation only; no prospective clinical trial data; regulatory path unclear; 5–10 year horizon realistic |
| Evidence Strength | 5 | 90.48% sensitivity / 100% specificity in clinical plasma samples is credible but sample size is unstated; abstract-only limits full assessment |
Key quantitative result: 90.48% sensitivity, 100% specificity at ≥0.01% VAF for KRAS/EGFR/PIK3CA in clinical plasma cfDNA
External validation: Not reported in abstract
Main limitation: Sample size not reported; abstract-only; no prospective cohort validation; head-to-head comparison with ddPCR or NGS not described
Equity implications: POC/smartphone readout is a significant equity asset for low-resource and low-income country settings; could reduce dependence on centralized lab infrastructure. Risk: implementation would still require trained personnel and cold-chain reagent supply
Evidence Maturity: Exploratory ✓ (confirmed)
Article 2 — MTAP-deleted thoracic malignancies clinicogenomic landscape (PMID 42172559)
🟠 Novel treatment | JCO Precision Oncology | Retrospective multinational cohort, n=15,942
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | MTAP as a synthetic lethal target is known; this study's novelty is cross-national reproducibility at scale and characterization of actionable driver co-occurrence — confirmatory rather than paradigm-shifting |
| Clinical Relevance | 7 | Directly informs combination trial design for MTAP-targeted agents (PRMT5/MAT2A inhibitors in development); co-occurrence with EGFR/ALK/ERBB2 has immediate implications for trial stratification |
| Population Reach | 7 | Lung cancer is the world's most common cancer killer; 8–20% MTAP deletion prevalence translates to hundreds of thousands of eligible patients annually |
| Implementation Speed | 5 | MTAP inhibitor trials are active but no approved agent yet; biomarker landscape study accelerates but does not itself deliver clinical change; 3–7 year horizon |
| Evidence Strength | 7 | Large n (~16K), two independent nationwide cohorts (US AACR GENIE + Japanese C-CAT), cross-population reproducibility is a significant strength; abstract-only limits full methodological review |
Key quantitative result: MTAP deletion prevalence 8–20% in lung adenocarcinoma/SCC; co-occurrence with actionable drivers confirmed across both cohorts; lower TMB association
External validation: Two independent national registries provide mutual cross-validation
Main limitation: Retrospective registry data; clinical outcome data and survival by MTAP status not clearly reported in abstract; abstract-only
Equity implications: Japanese and US cohort inclusion is notable — findings are cross-ethnically validated, which strengthens generalizability. However, unrepresented populations (Africa, South/Southeast Asia) remain a gap
Evidence Maturity: Validated ✓ (confirmed — landscape characterization is validated; therapeutic application remains investigational)
Article 3 — In vivo gene therapy with CAR-T cells (PMID 42172553)
🟠 Novel treatment | Blood | Review with clinical proof-of-concept summary
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 9 | In vivo CAR-T generation is a paradigm shift — eliminates the core manufacturing bottleneck of conventional CAR-T; first clinical PoC elevates from conceptual to emerging reality |
| Clinical Relevance | 7 | Potentially practice-transforming for lymphoma/leukemia if safety/efficacy confirmed; but clinical data is early and this is a review article — not primary evidence |
| Population Reach | 7 | Lymphoid malignancies collectively affect millions; manufacturing barriers currently restrict access to ~10–15% of eligible patients in developed markets; global access implications are enormous |
| Implementation Speed | 2 | Clinical PoC only; safety profile, optimal gene delivery vector, manufacturing of delivery vehicle, and regulatory path are all early-stage; 7–12 year realistic horizon |
| Evidence Strength | 4 | Review design; medium classification confidence; no primary data in this article; capped appropriately |
Key quantitative result: No specific quantitative outcomes reported in abstract beyond "feasibility and antitumor activity" in clinical PoC reports
External validation: Review synthesis — underlying clinical PoC reports referenced but not detailed
Main limitation: Review article only; no original data; clinical PoC reports summarized but not independently analyzable; safety/durability unknown; classification confidence medium
Equity implications: If in vivo CAR-T eliminates ex vivo manufacturing, it could radically democratize access — currently CAR-T therapy costs $350K–$500K USD and is unavailable in most of the world. This is the highest-equity-potential article in the batch if it delivers clinically
Evidence Maturity: Exploratory ✓ (confirmed)
Article 4 — eGFR discordance and cardiopulmonary morbidity in SCD (PMID 42172505)
🟡 Underserved population | Blood Advances | Cross-sectional + propensity score overlap weighting, n=1,099
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | Novel application of eGFR discordance (already familiar to nephrology) to cardiopulmonary risk stratification in SCD; the hemolysis-driven mechanism is biologically coherent and the association with HF/PH is a new clinical finding |
| Clinical Relevance | 8 | High: both eGFR equations are already routinely ordered; discordance is trivially calculable; if validated prospectively, this could be implemented immediately without new tests or costs |
| Population Reach | 5 | ~100,000 SCD patients in the US; ~20 million worldwide — significant unmet need within this population, though absolute numbers are modest relative to other articles. Judged relative to high unmet need |
| Implementation Speed | 7 | Near-term: requires no new technology, no new test orders, no new equipment — purely a recalculation from existing data; adoption could be very rapid pending guideline endorsement |
| Evidence Strength | 7 | Propensity score overlap weighting with n=1,099 is appropriate for a cross-sectional study; strong effect sizes (aOR 4.65 HF, 2.70 PH); appropriate comparator group; main weakness is cross-sectional design (no temporal data) |
Key quantitative result: eGFR discordance (cystatin C vs. creatinine) median adj. difference −14.20% in SCD; aOR for heart failure 4.65, pulmonary hypertension 2.70
External validation: No external cohort validation reported
Main limitation: Cross-sectional design — cannot establish temporality or whether discordance predicts incident cardiopulmonary events prospectively; single-institution data likely; abstract-only
Equity implications: Highly equity-positive: SCD predominantly affects Black Americans and sub-Saharan African populations who face systemic healthcare disparities; the eGFR discordance tool is zero-cost and zero-complexity, making it accessible at any point of care including resource-limited settings
Evidence Maturity: Validated (for association); Exploratory (for clinical utility) — I would refine this to Validated-Associational, pending prospective outcome validation before full clinical implementation
Article 5 — ASP-1929 photo-immunotherapy HICARi Phase II (PMID 42172495)
🟠 Novel treatment | J Gynecologic Oncology | Phase II single-arm, n=16
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 8 | First application of photo-immunotherapy (globally unique modality, only approved agent worldwide) to gynecologic cancers; genuinely novel indication expansion |
| Clinical Relevance | 6 | Addresses a real unmet need for RT-refractory gynecologic cancer, but n=16 and no efficacy data yet (trial ongoing); the "first-of-kind" framing is accurate but premature for practice impact |
| Population Reach | 4 | Rare indication — RT-refractory EGFR-positive vulvar/vaginal/cervical cancer is a small patient subset globally; technology currently limited to Japan |
| Implementation Speed | 3 | Early Phase II, Japan-only approval, requires specialized 690nm laser infrastructure, unclear regulatory path in US/EU; 7–10+ year realistic horizon for broader adoption |
| Evidence Strength | 4 | Phase II, n=16, single-arm, no comparator, only safety cohort established; efficacy endpoint results not yet reported |
Key quantitative result: 4-patient safety cohort established; 16 enrolled; primary efficacy data pending
External validation: None
Main limitation: Very small n; no comparator arm; efficacy data not yet mature; technology access restricted; abstract-only
Equity implications: Currently limited to Japan; EGFR testing requirement adds a biomarker selection step; cervical cancer disproportionately affects low-income populations in LMICs who would have no access to this technology
Evidence Maturity: Exploratory ✓ (confirmed)
Article 6 — Fault tree analysis of early AML treatment failure (PMID 42172714)
⚪ Promising preliminary | Curr Res Transl Med | Retrospective cohort + FTA, n=805
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | Application of industrial fault tree analysis to AML is methodologically novel; the clinical factors identified (RUNX1/TP53, low platelets, age, albumin, renal function) are individually known but the combinatorial logic is new |
| Clinical Relevance | 6 | If validated, XRC_ANY (32.6% of patients, HR 2.03) could meaningfully improve upfront treatment decision-making; but retrospective and unvalidated |
| Population Reach | 5 | AML incidence ~21,000/year in US; globally significant but not a large disease burden numerically |
| Implementation Speed | 4 | Requires prospective validation; all inputs are routinely available clinically; moderate pathway |
| Evidence Strength | 6 | BeatAML2 is a well-characterized, publicly available cohort; n=805 is reasonable; retrospective design limits causal inference; no external validation set |
Key quantitative result: XRC_ANY in 32.6% of patients; HR 2.03 for OS (median 297 vs. 861 days, p<0.0001)
External validation: None reported
Main limitation: Retrospective; single cohort; no external validation; FTA approach may overfit complex combinatorial logic to this dataset
Equity implications: All variables are routine clinical measures available at any center globally — equity-neutral in principle
Evidence Maturity: Exploratory ✓ (confirmed)
Article 7 — DA-EPOCH-R vs. R-CHOP in high Ki67 DLBCL (PMID 42172280)
⬜ Standard | PLoS One | Prospective observational + PSM, n=405
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 4 | Null result in a debated clinical question; East Asian population tolerability data is a modest novel contribution |
| Clinical Relevance | 6 | Directly relevant to lymphoma practice: DA-EPOCH-R use in high-Ki67 DLBCL is common and controversial; this null result has immediate clinical decision value in East Asian practice |
| Population Reach | 5 | DLBCL is the most common lymphoma globally; high Ki67 subset is significant but specific |
| Implementation Speed | 6 | Null result is immediately applicable — discourages an ineffective and toxic regimen |
| Evidence Strength | 6 | Prospective with PSM; but trial terminated early, only 37.9% achieved dose escalation, single-region population limits generalizability |
Key quantitative result: HR PFS 0.93 (NS), HR OS 1.28 (NS); 37.9% dose escalation achieved
Main limitation: Early termination; single region (East Asian); non-randomized; dose escalation failure confounds interpretation
Equity implications: East Asian population data fills a specific gap; findings may not generalize to other ethnic populations
Evidence Maturity: Exploratory (downgraded from potential Validated — early termination and poor dose escalation substantially limit conclusions)
Article 8 — DL model for cervical spinal cord compression on radiographs (PMID 42172670)
🟢 Near-term implementable | J Neurosurg Spine | Retrospective multi-institution DL, n=720
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | DL outperforming surgeons on radiographs is a well-established pattern; the specific cervical spine application with plain film (not MRI) input is the novel and clinically useful angle |
| Clinical Relevance | 7 | Using plain radiographs instead of MRI as the detection modality is highly practical; 94.67% vs. 69–71% accuracy is a clinically meaningful gap |
| Population Reach | 6 | Cervical myelopathy is common; greatest impact in low-resource settings lacking MRI |
| Implementation Speed | 5 | Requires regulatory clearance, deployment infrastructure, workflow integration; external validation done but limited to one additional center; 2–5 year horizon for resource-limited deployment |
| Evidence Strength | 6 | External validation at a second center; n=720 reasonable; retrospective design; generalizability across imaging equipment and demographics uncertain |
Key quantitative result: DL: 94.67% accuracy, AUC 0.99; surgeons: 69–71% accuracy; external validation: 93.33%
Main limitation: Retrospective; two centers only; unclear demographic diversity; no clinical outcome data (symptom-to-treatment pathway)
Equity implications: Plain radiograph input is a major equity asset — could assist non-specialist settings in LMICs where MRI is unavailable
Evidence Maturity: Exploratory → trending toward Validated; confirm as Exploratory pending broader validation
Article 9 — 30-day readmission prediction with limited EHR features (PMID 42172660)
🟢 Near-term implementable | JMIR Formative Research | Retrospective ML, n=50,000
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 4 | Readmission prediction with ML is a saturated field; the minimal feature set angle is a modest but practical contribution |
| Clinical Relevance | 5 | Practical finding for hospital implementation; but lacks external validation and clinical endpoint data |
| Population Reach | 7 | Hospital readmission is a universal healthcare problem; n=50K from NY state database |
| Implementation Speed | 5 | Concept is simple and data is already available in most EHRs; but external validation required before deployment |
| Evidence Strength | 5 | Large n but single-state, single-year (2019); multiple models tested but no external validation; modest performance gains over simpler methods not fully characterized |
Key quantitative result: Predictive signal retained with 11-feature set vs. 135-feature set; specific AUC/F1 values not reported in abstract
Main limitation: No external validation; 2019 data (pre-COVID); performance delta vs. simpler baselines not clearly quantified in abstract
Equity implications: Minimal feature approach could reduce socioeconomic bias from complex social determinants; but race/ethnicity equity analysis not mentioned
Evidence Maturity: Exploratory ✓
Article 10 — Routine CGP in NSCLC for co-mutation detection (PMID 42172690)
🟢 Near-term implementable | Cancer Treat Res Commun | Prospective multicenter cohort, n=437
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | TP53/STK11/KEAP1 co-mutations and their effect on immunotherapy are known; the prospective multicenter real-world NGS dataset adds supporting evidence rather than new discovery |
| Clinical Relevance | 7 | 70.3% of driver-negative NSCLC samples have clinically actionable co-mutations; directly supports broader NGS panel adoption in routine practice |
| Population Reach | 7 | NSCLC is among the highest-burden cancers globally; co-mutations affect the majority of the driver-negative subset |
| Implementation Speed | 6 | CGP is already available; the study supports expanding its use in settings where it's not yet standard |
| Evidence Strength | 6 | Prospective multicenter design is a strength; n=437 is moderate; abstract-only; Dutch single-country cohort may limit global generalizability |
Key quantitative result: 70.3% of actionable-driver-negative NSCLC harbored TP53/STK11/KEAP1 co-mutations
Main limitation: Abstract-only; single country (Netherlands); VUS interpretation challenge for KEAP1; no survival or immunotherapy outcome data reported
Equity implications: CGP cost/access barriers are significant globally; supports the policy case for reimbursement expansion
Evidence Maturity: Validated ✓ (for prevalence; outcome utility requires dedicated trial data)
Article 11 — Pediatric cancer genomic testing disparities at UCSF (PMID 42172550)
🟡 Underserved population | JCO Oncology Practice | Retrospective cohort + Poisson regression, n=758
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | Genomic testing disparities in pediatric oncology are increasingly documented; rural and age-based disparities add nuance |
| Clinical Relevance | 6 | Direct policy and practice implications for improving equitable access to precision oncology in children |
| Population Reach | 5 | ~16,000 pediatric cancer diagnoses/year in US; globally important but numerically moderate |
| Implementation Speed | 7 | Policy changes (e.g., insurance mandates, outreach programs) are near-term actionable; findings directly support advocacy |
| Evidence Strength | 6 | Population-based registry data; Poisson regression with appropriate confounders; single center (UCSF); national registry linkage is a strength |
Key quantitative result: Only 34.6% received genomic testing; rural RR 0.60, female RR 0.81, age 15–19 RR 0.69, lymphoma RR 0.49
Main limitation: Single institution; UCSF may not represent national practice; abstract-only
Equity implications: This article is an equity study — findings directly inform policy to address rural, sex, and age-based inequities in pediatric precision oncology
Evidence Maturity: Validated ✓
Article 12 — Hodgkin lymphoma outcomes in Czech Republic (PMID 42172116)
⬜ Standard | Klinická Onkologie | Registry retrospective, n=2,371
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 3 | Confirmatory registry data; age-based outcome disparity in HL is well-established |
| Clinical Relevance | 5 | Supports guideline evolution toward checkpoint inhibitors in elderly HL; useful regional real-world data |
| Population Reach | 4 | HL is a relatively uncommon lymphoma; Czech national data has limited global generalizability |
| Implementation Speed | 5 | Supports ongoing treatment evolution rather than defining it |
| Evidence Strength | 6 | Large 24-year national registry, n=2,371; strong survival data; but retrospective, single-country, limited to aggregate outcomes |
Key quantitative result: 10-year OS: <60 years: 94.2%/96.6%/92.6% (early/intermediate/advanced); ≥60 years: 74.2%/45.7%/52.0%
Main limitation: Registry-only; treatment heterogeneity across 24 years; elderly patients likely under-represented in novel agent cohorts
Evidence Maturity: Validated ✓
Article 13 — PEG-bispecific antibody CTC capture platform (PMID 42172175)
⚪ Promising preliminary | J Phys Chem B | In vitro platform study
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | Bispecific anti-PEG/anti-HER2 architecture with glutathione-triggered viable release is technically creative |
| Clinical Relevance | 2 | In vitro only; no clinical data; capped per non-human study rule (in vitro = non-human equivalent) |
| Population Reach | 4 | HER2+ cancers are common, but this is pre-clinical stage |
| Implementation Speed | 1 | Years from clinical application |
| Evidence Strength | 3 | In vitro only; cell line data; no patient samples |
Evidence Maturity: Exploratory ✓
Article 14 — Physics-informed DynUNet for brain metastasis segmentation (PMID 42172695)
⚪ Promising preliminary | Comput Methods Programs Biomed | Retrospective DL, n=105
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | Physics-informed neural network integration is methodologically novel in this context |
| Clinical Relevance | 4 | Modest segmentation gains; workflow integration and clinical outcome impact unclear |
| Population Reach | 5 | Brain metastases are common (~200,000 cases/year in US) |
| Implementation Speed | 3 | External validation at a single small cohort; regulatory and deployment hurdles remain |
| Evidence Strength | 5 | External validation is a strength; but n=105 is very small; gains are modest and λ-dependent |
Evidence Maturity: Exploratory ✓
Article 15 — Hippocampal stem cells and cognitive aging perspective (PMID 42172195)
⚪ Promising preliminary | PLoS Biology | Perspective/commentary
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | Reframes an old debate toward actionable direction; not a new empirical finding |
| Clinical Relevance | 3 | No data; no therapeutic; perspective piece only |
| Population Reach | 9 | Cognitive aging affects billions; if the therapeutic direction delivers, reach would be maximal |
| Implementation Speed | 1 | Conceptual/early basic science; 10+ year horizon minimum |
| Evidence Strength | 2 | Commentary; no primary data |
Evidence Maturity: Exploratory ✓
PHASE 3 — Ranking
Conflict Flags
No major cross-article conflicts. Articles 2 and 10 are complementary (both support comprehensive genomic profiling in lung cancer from different angles). Articles 3 and 5 address distinct mechanistic CAR/photo-immunotherapy spaces without contradiction.
Ranked Impact Score Table
Composite formula: Clinical Relevance (30%) + Population Reach (25%) + Scientific Novelty (20%) + Implementation Speed (15%) + Evidence Strength (10%)
| Rank | Article | Flag | Triage Score | Clinical Relevance | Population Reach | Scientific Novelty | Impl. Speed | Evidence Strength | Impact Score | Study Design |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Art. 4: eGFR discordance in SCD | 🟡 | 8 | 8 | 5 | 7 | 7 | 7 | 6.85 | Cross-sectional + PSM |
| 2 | Art. 2: MTAP-deleted thoracic malignancies | 🟠 | 8 | 7 | 7 | 6 | 5 | 7 | 6.60 | Retrospective multinational cohort |
| 3 | Art. 1: RECO-Cas liquid biopsy | 🔴 | 8 | 7 | 8 | 8 | 3 | 5 | 6.45 | Technical validation (clinical samples) |
| 4 | Art. 3: In vivo CAR-T gene therapy | 🟠 | 7 | 7 | 7 | 9 | 2 | 4 | 6.15 | Review + clinical PoC summary |
| 5 | Art. 10: Routine CGP in NSCLC | 🟢 | 6 | 7 | 7 | 5 | 6 | 6 | 6.35 | Prospective multicenter cohort |
| 6 | Art. 8: DL model for cervical cord compression | 🟢 | 7 | 7 | 6 | 6 | 5 | 6 | 6.15 | Retrospective multi-institution DL |
| 7 | Art. 5: ASP-1929 photo-immunotherapy HICARi | 🟠 | 7 | 6 | 4 | 8 | 3 | 4 | 5.25 | Phase II single-arm |
| 8 | Art. 6: Fault tree analysis AML | ⚪ | 7 | 6 | 5 | 6 | 4 | 6 | 5.55 | Retrospective cohort + FTA |
| 9 | Art. 7: DA-EPOCH-R vs R-CHOP DLBCL | ⬜ | 6 | 6 | 5 | 4 | 6 | 6 | 5.50 | Prospective observational + PSM |
| 10 | Art. 11: Pediatric cancer genomic testing disparities | 🟡 | 6 | 6 | 5 | 5 | 7 | 6 | 5.75 | Retrospective cohort + Poisson |
| 11 | Art. 12: Hodgkin lymphoma outcomes Czech Republic | ⬜ | 5 | 5 | 4 | 3 | 5 | 6 | 4.55 | Registry retrospective |
| 12 | Art. 9: 30-day readmission ML prediction | 🟢 | 6 | 5 | 7 | 4 | 5 | 5 | 5.25 | Retrospective ML |
| 13 | Art. 14: Physics-informed DynUNet brain mets | ⚪ | 5 | 4 | 5 | 6 | 3 | 5 | 4.55 | Retrospective DL + external validation |
| 14 | Art. 13: PEG-bispecific CTC capture platform | ⚪ | 5 | 2 | 4 | 6 | 1 | 3 | 3.25 | In vitro platform study |
| 15 | Art. 15: Hippocampal stem cells aging perspective | ⚪ | 5 | 3 | 9 | 5 | 1 | 2 | 4.35 | Perspective/commentary |
Note: Articles 5 and 8 tied at 6.15; Art. 8 ranked above Art. 5 on Clinical Relevance tie-breaker (7 vs. 6). Articles 8 and 3 also tied at 6.15; Art. 10 was re-scored above these as 6.35 — ranking corrected below.
Corrected Final Order (top 6):
| Rank | Article | Impact Score |
|---|---|---|
| 1 | Art. 4 — eGFR discordance in SCD | 6.85 |
| 2 | Art. 2 — MTAP thoracic malignancies | 6.60 |
| 3 | Art. 10 — Routine CGP in NSCLC | 6.35 |
| 4 | Art. 1 — RECO-Cas liquid biopsy | 6.45 |
| 5 | Art. 3 / Art. 8 — In vivo CAR-T / DL spine | 6.15 (tie) |
Tie-break Art. 1 vs. Art. 10: Art. 1 scores higher on Scientific Novelty (8 vs. 5) but lower on Implementation Speed (3 vs. 6) and Evidence Strength (5 vs. 6). Clinical Relevance tied at 7. On the composite, Art. 1 = 6.45 and Art. 10 = 6.35 — Art. 1 ranks 3rd, Art. 10 ranks 4th.
Final Definitive Ranking:
| Rank | Article | Impact Score | OpenClaw Triage | Flag |
|---|---|---|---|---|
| #1 | Art. 4 — eGFR discordance & cardiopulmonary morbidity in SCD | 6.85 | 8 | 🟡 |
| #2 | Art. 2 — MTAP-deleted thoracic malignancies | 6.60 | 8 | 🟠 |
| #3 | Art. 1 — RECO-Cas liquid biopsy | 6.45 | 8 | 🔴 |
| #4 | Art. 10 — Routine CGP in NSCLC | 6.35 | 6 | 🟢 |
| #5 | Art. 3 — In vivo CAR-T gene therapy | 6.15 | 7 | 🟠 |
| #6 | Art. 8 — DL model for cervical cord compression | 6.15 | 7 | 🟢 |
| #7 | Art. 11 — Pediatric genomic testing disparities | 5.75 | 6 | 🟡 |
| #8 | Art. 6 — Fault tree analysis AML | 5.55 | 7 | ⚪ |
| #9 | Art. 7 — DA-EPOCH-R vs R-CHOP DLBCL | 5.50 | 6 | ⬜ |
| #10 | Art. 5 — ASP-1929 photo-immunotherapy | 5.25 | 7 | 🟠 |
| #11 | Art. 9 — 30-day readmission ML | 5.25 | 6 | 🟢 |
| #12 | Art. 12 — HL outcomes Czech Republic | 4.55 | 5 | ⬜ |
| #13 | Art. 14 — Physics-informed DynUNet | 4.55 | 5 | ⚪ |
| #14 | Art. 15 — Hippocampal stem cells aging | 4.35 | 5 | ⚪ |
| #15 | Art. 13 — PEG-bispecific CTC capture | 3.25 | 5 | ⚪ |
Rank Justification Paragraphs
#1 — Art. 4 🟡 Olaniran et al., Blood Advances: This study rises to the top not because of groundbreaking mechanistic novelty, but because it identifies a free, zero-friction clinical tool — eGFR discordance between cystatin C and creatinine — that could immediately flag life-threatening cardiopulmonary risk in sickle cell disease patients. With aOR 4.65 for heart failure and 2.70 for pulmonary hypertension, the effect sizes are clinically substantial. Both eGFR formulas are already ordered routinely. The propensity-score-weighted design is appropriate for the cross-sectional comparison. Critically, this addresses Black patients with SCD — a population that has historically suffered diagnostic neglect and poor access to specialized care. The near-zero implementation barrier is decisive for the top ranking.
Why it matters: A free calculation from routine labs could identify sickle cell patients at highest risk of heart failure and pulmonary hypertension — diseases that silently kill them decades early.
#2 — Art. 2 🟠 Ikushima et al., JCO Precision Oncology: The power here is the cross-national validation across ~16,000 patients in US and Japanese databases confirming MTAP deletion prevalence and its co-occurrence pattern with actionable drivers. PRMT5 and MAT2A inhibitors targeting MTAP-deleted tumors are in active clinical trials; this study provides the patient-stratification foundation those trials need. The cross-ethnic reproducibility of the prevalence data is a genuine scientific contribution that advances trial design globally.
Why it matters: For lung cancer patients whose tumors lack the usual targetable mutations, MTAP deletion may be the next actionable molecular handle — and this study maps exactly who they are.
#3 — Art. 1 🔴 Guo et al., Science Advances: RECO-Cas achieves 0.01% VAF sensitivity in clinical plasma — a level that challenges the current gold standard of digital PCR — while being deployable on a smartphone. The scientific novelty of combining CRISPR-Cas12a with an Argonaute-nicked artificial activator is genuine. The POC format directly addresses access equity. However, the missing sample size, abstract-only access, and lack of comparative benchmarking prevent a higher ranking. This is the highest-potential early-stage finding in the batch.
Why it matters: If this CRISPR-based test delivers on its promise at scale, cancer monitoring via liquid biopsy could move from centralized labs to rural clinics and low-income countries.
#4 — Art. 10 🟢 Soekhoe et al., Cancer Treat Res Commun: The 70.3% co-mutation prevalence in driver-negative NSCLC is not surprising in isolation, but this prospective multicenter dataset provides clean, practice-facing evidence supporting the expansion of comprehensive NGS panel use in routine lung cancer care. The STK11 exon 1 isoform findings are an emerging area warranting further attention.
Why it matters: Seven in ten lung cancer patients without classic driver mutations carry genomic alterations that predict immunotherapy failure — but many clinical labs still don't test for them.
#5 — Art. 3 🟠 Wagner, Elsallab, Maus, Blood: In vivo CAR-T is potentially the most transformative concept in this batch — it would eliminate the $350K–$500K manufacturing cost and access bottleneck of conventional CAR-T. First-in-human clinical proof of concept has now been reported. The ranking is held back by the review design, medium classification confidence, and the absence of quantitative outcomes. This is the highest-ceiling, lowest-certainty article in the batch.
Why it matters: CAR-T therapy currently reaches only a fraction of the patients who need it. If tumor-killing immune cells can be generated inside the body rather than in a factory, the economics and logistics of cell therapy change permanently.